P/E at 36.05 vs Industry's 34.84: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Industry Norms

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.05, slightly above the Pharmaceuticals & Biotechnology industry average of 34.84. This premium, though not excessive, suggests that the market attributes a somewhat higher growth or quality expectation to the stock compared to its peers. Given the sector’s typical valuation range, this premium is consistent with the company’s large-cap status and its historical performance track record. The market cap of ₹4,37,735 crore further cements its position as a heavyweight within the sector.

However, the premium also invites scrutiny — previously rated Buy, what is Sun Pharmaceutical Industries Ltd’s current rating? The valuation must be justified by consistent earnings growth and operational stability, especially in a sector where regulatory and competitive pressures can be significant.

Performance Across Timeframes: A Consistent Outperformer

Examining the stock’s returns relative to the Sensex reveals a pattern of consistent outperformance. Over one year, Sun Pharmaceutical Industries Ltd gained 7.09%, while the Sensex declined by 7.81%. This positive alpha extends to shorter and longer timeframes: the three-month return is 7.84% versus the Sensex’s -9.25%, and the year-to-date performance is 6.48% compared to the Sensex’s -12.01%. Even over five years, the stock has delivered a remarkable 164.96% gain, far exceeding the Sensex’s 53.86% rise.

Short-term momentum, however, shows some moderation. The stock’s one-week return is slightly negative at -0.18%, though this still outperforms the Sensex’s -3.68%. The one-day gain of 0.37% trails the Sensex’s 0.50% but remains positive. This suggests a recent pause or consolidation phase after a strong run — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Moving Average Configuration: Signs of Strength Amid Short-Term Resistance

The technical setup for Sun Pharmaceutical Industries Ltd is revealing. The stock currently trades above its 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained upward trend over medium and long-term horizons. However, it remains below its 5-day moving average, indicating some short-term resistance or profit-taking pressure.

This configuration often points to a stock that is in a recovery phase or consolidating after a recent rally. The fact that it is close to its 52-week high — just 2.82% away from ₹1885.65 — further supports the notion of underlying strength. The stock has also reversed gains after two consecutive days of decline, suggesting renewed buying interest. Is this a sustainable breakout or a temporary pause before a pullback? The moving averages will be critical levels to watch in the coming sessions.

Sector Context: Pharmaceuticals & Biotechnology Showing Broad Strength

The Pharmaceuticals & Biotechnology sector has delivered mostly positive results recently, with 9 out of 11 stocks declaring positive earnings, one flat, and only one negative. This broad-based strength provides a supportive backdrop for Sun Pharmaceutical Industries Ltd, which is among the largest players in the sector.

Sector tailwinds include ongoing demand for generic drugs, innovation in specialty medicines, and increasing global market penetration. However, regulatory scrutiny and pricing pressures remain challenges. The sector’s positive earnings momentum contrasts with the Sensex’s recent weakness, highlighting the defensive qualities of pharmaceutical stocks in volatile markets.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 80.0 and a Mojo Grade of Strong Buy assigned on 5 May 2026. The reassessment reflects updated analysis of valuation, performance, and technical factors. The stock’s premium valuation and consistent outperformance underpin the positive view, but the short-term technical caution tempers enthusiasm. Should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Conclusion: Data Reflects a Balanced but Positive Outlook

The data for Sun Pharmaceutical Industries Ltd reveals a stock trading at a slight valuation premium within a broadly positive sector environment. Its consistent outperformance over multiple timeframes, including a 7.09% gain over one year against a Sensex decline, underscores its resilience. The moving average configuration suggests a stock in recovery with some short-term resistance, while sector earnings remain predominantly positive.

Previously rated Buy, the reassessment reflects these nuanced factors without signalling a dramatic shift. Investors may find the valuation justified by the company’s market position and earnings stability, but the short-term technical signals warrant close monitoring. What is the current rating for Sun Pharmaceutical Industries Ltd given these mixed signals?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →